Skip to main content

Table 4 Correlation between clinico-pathological features and the expressions of Hsp90-beta and annexin A1 in lung cancer

From: Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients

Parameter Group N Expression of Hsp90-beta Expression of annexin A1
Low (%) Moderate (%) High (%) χ2value P value Low (%) Moderate (%) High (%) χ2value P value
Gender             
  Male 73 12(16.4) 22(30.1) 39(53.4) 4.49 0.105 18(24.7) 26(35.6) 29(39.7) 5.09 0.078
  Female 23 2(8.7) 3(13) 18(78.3) 2(8.7) 6(26.1) 15(65.2)
Ages             
  <60 54 8(14.8) 13(24.1) 33(61.1) 0.251 0.882 8(14.8) 20(37) 26(48.1) 2.798 0.247
  ≥60 42 6(14.3) 12(28.6) 24(57.1) 12(28.6) 12(28.6) 18(42.9)
Smoking             
  0 37 3(8.1) 6(16.2) 28(75.7) 8.28 0.082 5(13.5) 10(27) 22(59.5) 3.856 0.248
  0.1–40 12 1(8.33) 5(41.67) 6(50) 2(16.7) 5(41.7) 5(41.7)
  >40 47 10(21.3) 14(29.8) 23(48.9) 13(27.7) 17(36.2) 17(36.2)
Histology             
  LAC 39 8(20.5) 9(23.1) 22(56.4) 8.16 <0.05 7(17.9) 9(23.1) 23(59) 7.513 <0.05
  LSCC 41 5(12.2) 13(31.7) 23(56.1) 10(24.4) 19(46.3) 12(29.3)
  SCLC 11 1(9.1) 1(9.1) 9(81.82) 2(18.2) 2(18.2) 7(63.6)
  Others 5 0(0) 2(40) 3(60) 1(20) 2(40) 2(40)
Pathological grade             
  Poorly 26 1(3.8) 4(15.4) 21(80.8) 31.26 <0.0005 2(7.7) 2(7.7) 22(84.6) 38.26 <0.0005
  Moderately 33 1(3.03) 12(36.36) 20(60.61) 5(15.2) 21(63.6) 7(21.2)
  Well 22 11(50) 6(27.3) 5(22.7) 10(45.5) 5(22.7) 7(31.8)
  Undifferentiated 15 1(6.67) 3(20) 11(73.33) 3(20) 4(26.7) 8(53.3)
Lymphatic invasion             
  N0 41 12(29.3) 18(43.9) 11(26.8) 31.02 <0.0005 17(41.5) 13(31.7) 11(26.8) 19.97 <0.0005
  N1 40 1(2.5) 5(12.5) 34(85) 2(5.5) 17(34.5) 21(60)
  N2 11 0(0) 2(18.2) 9(81.8) 1(9.1) 1(9.1) 9(81.82)
  N3 4 0(0) 0(0) 4(100) 0(0) 0(0) 4(100)
hydrothorax             
  Absent 82 13(15.9) 23(28) 46(56.1) 2.51 0.285 18(22) 29(35.4) 35(42.7) 2.25 0.324
  Present 14 1(7.1) 2(14.3) 11(78.6) 2(14.3) 3(21.4) 9(64.3)
T stage             
  T1 – T2 57 11(19.3) 22(38.6) 24(42.1) 14.72 0.001 17(29.8) 23(40.4) 17(29.8) 14.83 0.001
  T3 – T4 28 2(7.1) 2(7.1) 24(85.7) 1(3.6) 7(25) 20(71.4)
  Unavailable 11 1(9.1) 1(9.1) 9(81.82) 2(18.18) 2(18.18) 7(63.64)
pTNM             
  IB 3 1(33.3) 2(66.7) 0(0) 11.449 0.022 0(0) 3(100) 0(0) 9.97 0.008
  IIA-IIB 53 10(18.9) 19(35.8) 24(45.3) 16(30.2) 20(37.7) 17(32.1)
  IIIA-IIIB 25 2(8) 3(12) 20(82) 2(8) 6(24) 17(68)
  IV 4 0(0) 0(0) 4(100) 0(0) 1(25) 3(75)
  Unavailable 11 1(9.1) 1(9.1) 9(81.82) 2(18.18) 2(18.18) 7(63.64)
Imaging             
  Central 43 5(11.63) 15(34.88) 23(53.49) 2.68 0.261 11(20.9) 16(41.9) 16(37.2) 2.07 0.356
  Ambient 49 9(18.37) 10(24.49) 30(57.14) 8(20.4) 16(32.7) 25(46.9)
  Unavailable 4 0(0) 0(0) 4(100)    1(25) 0(0) 3(75)   
  1. p < 0.05, SCLC compared with LSCC and LAC, respectively; p < 0.05, LSCC compared with LAC and SCLC, respectively; p<0.0005, N0 compared with N1, N2, and N3, respectively; p<0.0005, N0 compared with N1, N2, and N3, respectively; p = 0.022, IB and IIA-IIB compared with IIIA-IIIB and IV, respectively; p = 0.022, IB and IIA-IIB compared with IIIA-IIIB and IV, respectively; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; SCLC, small cell lung cancer; LCLC, large cell lung cancer; Smoking, pack years of smoking.